MedTrace Logo

microRNAs in the Diagnosis of Atherosclerotic Plaque Instability

NCT05680935 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-07-16

No results posted yet for this study

Summary

It's a non-randomized, intervention, prospective, single-center study.

The aim of the work is to identify of biomarkers of unstable atherosclerosis in brachiocephalic arteries

Tasks:

* identify microRNAs, the expression of which is characteristic of unstable atherosclerotic lesions;
* to assess the relationship of miRNA and trimethylamine N-oxide with the progression of unstable atherosclerotic lesions;
* to determine the effect of the level of plasma trimethylamine N-oxide on the progression of atherosclerotic lesions.

Conditions

  • Atherosclerosis of Artery

Interventions

DIAGNOSTIC_TEST

blood microRNA

all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

DIAGNOSTIC_TEST

plaque and intima microRNA

The resulting surgical material will be sent for microRNA isolation.

DIAGNOSTIC_TEST

histological examination of the plaque

The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.

DIAGNOSTIC_TEST

blood level trimethyl N-oxide

all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Sponsors & Collaborators

  • I.M. Sechenov First Moscow State Medical University

    lead OTHER

Principal Investigators

  • Anastasiia Lomonosova, no · I.M. Sechenov First Moscow State Medical University (Sechenov University)

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2024-02-28
Completion
2024-02-29

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05680935 on ClinicalTrials.gov